Ensysce Biosciences $ENSC Read from its own SEC filings · nothing written, nothing inferred
🫧 Edgar looked up ENSYSCE BIOSCIENCES, INC. ($ENSC). Last filing: 8-K (5.03 Amendments to Articles or Bylaws; Change in Fiscal Year), 2026-09-29. 17 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-06-05.
🔖 Exposure: revenue $5.1M (FY2025). Experience: revenue down 2.8% on the year, up 9.4% a year over 4 years; operating margin -202.1%, down from -129.2%. Soundness: equity 43.1% of assets, return on equity -316.6%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $2.6M and $12.2M next year (method v4.1: its own 5-year record of growth weighed at 57% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $2.3M to $13.6M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -202.1% against a -3.8% median; growth -2.8% against 13.7%.
Speed and cash · fiscal 2025
Both views must agree for a label · a description, not advice.
| Cash flow (op · inv · fin · free) | −$8M · −$0M · $9M · −$8M |
| Investment book (cash · short · long) | $4M · — · — · current ratio 1.59 |
| Revenue swing · equity of assets | 46.0% · 43.1% |
Ensysce Biosciences is growing faster than its size class, with revenue that swings more. Its own audited SEC figures.
The figures, as filed
| Fiscal year end | 2025-12-31 |
| Revenue | $5M |
| Revenue, on the year | −2.8% |
| Revenue, a year over the record | 9.4% |
| Operating margin | −202.1% |
| Operating margin, prior year | −129.2% |
| Net margin | −200.8% |
| Research and development | $10M · 204.8% of revenue |
| Total debt | — |
| Equity of assets | 43.1% |
| Return on equity | −316.6% |
| Payout of profit | — |
| Dividend per share | — |
| Earnings per share | $-3.98 |
| Book value per share | $1.26 |
| Revenue per share | $1.98 |
| Shares outstanding | 2,557,377 |
| Audited years read | 5 |
Peers: the median of 114 filers with $50M+ revenue in pharmaceutical preparations.
Health HarborEnsysce Biosciences sails as: Weathered boat
Health watch · 12 monthsExchange listing notice or transfer ×2Director or officer change ×4
Sailing speed follows growth: 26.2% a year crosses the harbor in 30 seconds.
🌊 Visit the Bay →- operating cash flow was negative
- revenue is hard to predict: its 80% range is ±65%
Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.
- 8-K · 2026-09-29 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-25 · 8.01 Other Events
- 8-K · 2026-08-24 · 8.01 Other Events
- 10-Q · 2026-08-13
- 8-K · 2026-08-13 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits
- 8-K · 2026-08-06 · 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modifications to Rights of Security Holders; 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company